

Clarivate Analytics

*Scientific information to support
Healthcare in Romania*

**Romanian Hospitals Network
Romanian Ministry of Health**

Who is Clarivate Analytics?

Clarivate Analytics is the global leader in trusted insights and analytics that accelerate the pace of innovation.

Trusted by the world's top universities, corporations, hospitals and brands, Clarivate Analytics is on a bold entrepreneurial path to help customers accelerate how quickly they turn new ideas into solutions and help them sustain and grow their business as they face continual challenges — shrinking budgets, rapidly growing data coming from diverse new sources, and innovation remaining central to competitiveness.

It's more critical than ever to provide these innovators with insights they can trust. Clarivate has a long tradition in all aspects of the innovation lifecycle.



Scientific and Academic
Research



Life Sciences



Patent Research,
Intelligence and Services



Trademark Research and
Protection



Domain and Brand
Protection



Intellectual Property
Management

Clarivate Analytics helps Hospitals to

Direct patient to recruiting clinical trials in Romania, attract company sponsors, follow standards of care and get the latest approved medicines at the best price

Clinical Trials Intelligence

- ❑ Which drugs are currently being studied for various diseases of interest?
- ❑ Which trial design elements (incl. selection of biomarkers, endpoints, patient segments) were relevant in predicting the success of those drugs?
- ❑ Which trials are currently recruiting patients in locations accessible to Romanian hospitals patients?
- ❑ See which patient sub-groups were included in trials that had more success achieving endpoints
- ❑ How long should we expect a particular trial phase to last?
- ❑ How are other institutions designing their clinical trials (treatment arms, inclusion/exclusion criteria, biomarkers)?
- ❑ How does Romania compare to other countries when it comes to the number, phase, enrollment of clinical trials?
- ❑ Which hospitals in Romania are most active in clinical trials, with additional insights into the effectiveness of those sites / organisations.

CORTELLIS CLINICAL TRIALS

Standards of care

- ❑ Identify the best treatment per type of patient
- ❑ Be up to date about disease knowledge
- ❑ Which of those drugs have already been proven safe and effective for other conditions in some markets?
- ❑ What are the disease incidence and prevalence rates in Europe? How are those expected to change over the coming years?
- ❑ Are there particular subgroups of disease populations that are more relevant than others?
- ❑ What are the best practices when it comes to treating various diseases?
- ❑ Which drugs are currently approved for various conditions in different countries?

CORTELLIS DISEASE BRIEFING

INCIDENCE AND PREVALENCE DATABASE

Medicines Supply

- ❑ Get an overview of all the medicines available with price by manufacturer
- ❑ Forecast stocks to avoid shortage
- ❑ Who is currently marketing drugs of interest and where?
- ❑ How are the prices for drugs of interest differing across marketers and countries?
- ❑ When do the patents and exclusivities expire in Romania?
- ❑ Who is manufacturing the active substance for the drugs of interest?
- ❑ How experienced are the marketers selling their products in Romania?

NEWPORT

Clinical Trials
(slides 5-8)

Standards of care
(slides 9-11)

Medicines Supply
(slides 12-14)

Romanian Ministry of Health

Centralized health system. With more than 40000 medical doctors, and 400 hospitals spread within the country, Romania offers multiple opportunities to perform clinical studies in many desired indications.

One of the most attractive aspects of the clinical research in Romania is the high number of eligible patients, the high enrollment rates and fast recruitment (GCT, 2017)

The legislation and regulations of the country are in line with the EU Directives and Guidelines and the principles of conducting the clinical trials are driven by the Declaration of Helsinki. Romanian Competent Authority and Ethics Committee are two official bodies involved in running the clinical trials.

Cortellis Clinical Trials Intelligence

Intelligence gained from Global clinical trials gathered from all the major Global trial registries is combined with manually curated scientific knowledge from full text journal articles, conferences and company communications to provide you the best intelligence to inform your clinical development and improve patient access to innovative therapeutics:

- Gain insights into patient sub-populations defined within successful and less successful clinical trials
- Learn from the trial design and outcomes of clinical trials from the best Global clinical centres
- Understand likely patient experiences and outcomes regarding efficacy and toxicity
- Understand growth and likely economic benefit of comparator countries Globally
- Gain comparable data and insights into the volumes and effectiveness of clinical trials that involve Romanian sponsors / collaborators / sites.

CLINICAL TRIALS PERFORMANCE

1- Gather content from multiple sources, including registries, conferences, press releases and journals, compiled into a single record. This saves hospitals and Principal Investigators time when looking for information from various registries about a particular trial and additional information that isn't available from registries alone.

2- Gain insights into the volume of trials sites and activity across Romania.

The screenshot displays a web application interface for clinical trials performance. It features a left-hand navigation menu with several filter categories: Biomarker Type (Physiological, Proteomic, Genomic), Biomarker Role (Therapeutic effect marker, Disease marker, Toxic effect marker), Interventions (ivacaftor, tiotropium bromide, azithromycin), Site Name (University of Texas, University of Rochester, University of Michigan), and Contact Name (GSK Clinical Trials, Boehringer Ingelheim, Novartis Pharmaceuticals). A 'SHOW ALL FILTERS' dialog box is open, showing a search bar for 'Contact Name' and a list of filter options including Condition, Patient Segment, Biomarker, Biomarker Type, Biomarker Role, Interventions, Site Name, Contact Name, Sponsors/Collaborators, Phase, Recruitment Status, Organization Type, Action, Class, Start Date, and End Date. The 'Contact Name' filter is selected, and the dialog shows a list of results: GSK Clinical Trials (39), Boehringer Ingelheim (32), Novartis Pharmaceuticals (26), Bayer Study Director (25), Jonathan Bernstein (25), Minnie Abromowitch (23), Narayana Gowda (18), Robert J. Fallon (17), Leo Mascarenhas (16), Eugenia Chang (16), Medical Monitor (16), Alyssa T. Reddy (16), Mark A. Ranalli (16), and Steven J. Kuerbitz (16). Below the dialog, the main search area shows the search term 'barth' and a 'Look up' button. The search results are displayed in a table with columns for filter categories and counts. The results are: Jay Barth (2) and Jay Barth, MD (2). The 'SHOW ALL FILTERS' dialog is also visible at the bottom of the screen, showing the search term 'barth' and the 'Look up' button.

CLINICAL TRIALS PERFORMANCE

As many as 30% of Phase 3 trials fail due to lack of patient recruitment. As such, a good site selection and performance is crucial for hospitals to benchmark themselves

Endpoint Types	Efficacy; Pharmacokinetics; Safety
Enrollment Count	35
Evaluable Subject Count	
Start Date	30-Apr-2013
End Date	30-Apr-2017 (Estimated)
Primary Endpoint Completion Date	30-Apr-2017 (Anticipated)
Enrollment End Date	31-Dec-2016 (Actual)
Enrollment Period	44.06 Months
Enrollment Rate	0.79 Patients/Month
First Received Date	21-Dec-2012
Last Change Date	17-Feb-2017
Added Date	07-Jan-2013

CLINICAL TRIALS PERFORMANCE

Under the latest research and clinical insights into patient sub-groups and biomarkers applied within the clinic

Search Patient Segment Look up Non-Hierarchical List Hierarchical List Select filter view **Frequency**

Condition	Count
<input checked="" type="checkbox"/> Breast tumor - Subjects with Advanced/Metastatic Breast Cancer/Stage IV Breast Cancer	(39)
<input type="checkbox"/> Breast tumor - Subjects with Treatment Resistant Disease	(20)
<input type="checkbox"/> Breast tumor - Subjects with Locally Advanced Breast Cancer	(15)
<input type="checkbox"/> Solid tumor - Subjects with Advanced/Metastatic Solid Tumors	(14)
<input type="checkbox"/> Solid tumor - Subjects with Treatment Resistant Disease	(12)
<input type="checkbox"/> Breast tumor - Subjects with HER-2 Negative Breast Cancer	(11)
<input type="checkbox"/> Lung tumor - Subjects with Advanced Stage Lung Cancer - Subjects with metastatic/stage IV lung cancer	(11)
<input type="checkbox"/> Lung tumor - Subjects with Advanced Stage Lung Cancer	(11)
<input type="checkbox"/> Breast tumor - Subjects with HER-2 Positive Breast Cancer	(10)
<input type="checkbox"/> Breast tumor - Subjects with Stage III Breast Cancer	(9)
<input type="checkbox"/> Prostate tumor - Subjects with Advanced/Metastatic Prostate Cancer	(9)
<input type="checkbox"/> Prostate tumor - Subjects with Stage IV Prostate Cancer	(9)
<input type="checkbox"/> Prostate tumor - Subjects with Treatment Resistant Disease	(8)

SHOW ALL FILTERS

Search Biomarker Look up Select filter view **Frequency**

Condition	Count
<input checked="" type="checkbox"/> HER2	(11)
<input checked="" type="checkbox"/> Alanine transaminase	(4)
<input type="checkbox"/> Aspartate aminotransferase	(3)
<input type="checkbox"/> Creatinine	(3)
<input type="checkbox"/> Estrogen receptor	(3)
<input type="checkbox"/> Tumor mass	(3)
<input type="checkbox"/> Androgen receptor	(2)
<input type="checkbox"/> Bilirubin	(2)
<input type="checkbox"/> CA-125 antigen	(2)
<input type="checkbox"/> CA19-9 antigen	(2)
<input type="checkbox"/> Carcinoembryonic antigen	(2)

STANDARDS OF CARE

Disease Briefings in Cortellis offer a full overview of the condition including diagnosis, prevention, different types of treatment as well as drugs available in the market and under development

- FACTS ABOUT ARTERIAL HYPERTENSION
- Pathophysiology
- Risk Factors
 - Genetics
- Epidemiology
- Morbidity and Mortality
- Cost
- DIAGNOSIS
- Screening
- PREVENTION
- TREATMENT
 - Lifestyle Modification
 - Pharmacotherapy
 - Diuretics
 - Beta-adrenoceptor Antagonists
 - Imidazoline I1 Receptor Agonists
 - The Renin-Angiotensin System
 - ACE Inhibitors
 - ACE2 Modulators
 - Renin Inhibitors
 - Angiotensin Receptor Blockers
 - Aldosterone Antagonists

Arterial Hypertension

Disease Briefing

Latest Headlines

Multimedia

Glossary

Suggested Reading

Related Information

Sources

Highlight Search Terms & Synonyms < Previous Next >


DISEASE BRIEFINGS

[Expand all](#)

FACTS ABOUT ARTERIAL HYPERTENSION

Pathophysiology

When the heart beats it produces a pressure wave in the arteries. The peak of this wave is called systolic pressure and the lowest pressure between heartbeats is called diastolic pressure. Both systolic and diastolic measures are important in determining hypertension. Hypertension is defined by both WHO and the American Heart Association as a systolic blood pressure of 140 or higher and diastolic pressure of 90 or higher, with various grades or stages of hypertension. The Joint National Committee (JNC 8) specifies a higher cutoff point for systolic blood pressure (150 mmHg) in patients with chronic kidney disease. [Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines \(JNC 8\).](#)



Arterial Hypertension: Blood Pressure Classifications and Cut Off Points

[Enlarge](#)

Abnormally high blood pressure causes the heart to work harder than normal and leaves the heart and arteries under strain. If hypertension is not treated and the heart is forced to work harder and harder for a prolonged period of time, it becomes enlarged and the arteries become scarred, hardened and less elastic, a process called arteriosclerosis. The hardened and narrowed arteries do not deliver an adequate amount of blood to the body's organs and tissues, meaning that they cannot function properly. Blood flow is restricted through the narrowed arteries, depriving a part of the body of its blood supply altogether.


STANDARDS OF CARE

Disease Briefings in Cortellis helps you identify all the drugs available for hypertension (for example) according to specific mechanism of action like Calcium channel blocker shown here.

Calcium channel blockers		
Verapamil hydrochloride (Isoptin)	Abbott	1963
Diltiazem hydrochloride (Cardizem)	Mitsubishi Tanabe Pharma	1974 (Japan)
Nifedipine (Adalat)	Bayer	1975
Nicardipine hydrochloride (Cardene)	Astellas Pharma/Mitsui Chemicals/Bayer	1981 (Japan)
Nitrendipine (Bayotensin)	Bayer	1985 (Germany)
Felodipine (Plendil)	AstraZeneca	1988 (Denmark, Sweden)
Nilvadipine (Nivadil)	Astellas Pharma	1989 (Japan)
Isradipine (Lomir)	Novartis	1989 (U.K.)
Amlodipine besylate (Istin)	Pfizer	1990 (U.K.)

STANDARDS OF CARE

The **targetscape** for hypertension shown here displays an overall cellular and molecular landscape or comprehensive network of connections among the current therapeutic targets for the treatment of the condition and their biological actions.



MANUFACTURING/SUPPLY: PLANNING TO MEET THE DEMAND FOR MEDICINES

Newport provides launches data including marketers, brand names, dose forms and description of the product by country and date. Pack prices are also included to make it easier for Hospitals to identify products and providers with more convenient prices.

Search Criteria : Product Name begins with **amlodipine** and Launch Country In **Bulgaria** or **Romania** or **Slovenia** and Pack Launch Date is after **1/1/2012**

Search returned **187** records.

 Save Search

Worldwide Pack Price Search Results										
Pages: 1 2 3 4 5 6 7										
Dose Form	Strength	Active Ingredient	Trade Name	▲ Marketer	Corporate Group	Launch Country	Pack Description	Latest Retail Pack Price	Latest Hospital Pack Price	Pack Launch Date
Tablet	10MG	amlodipine besylate; atorvastatin calcium	LUXTANOR	ACTAVIS	Allergan Plc	Bulgaria	F.C.TABS 10 10MG 30	LEV 9.81	LEV 9.54	31 Jul 2014
Tablet	10MG	amlodipine besylate; atorvastatin calcium	LUXTANOR	ACTAVIS	Allergan Plc	Bulgaria	F.C.TABS 5 10MG 30	LEV 8.68	LEV 8.44	31 Jul 2014
Capsule	10MG	ramipril; amlodipine besylate	VIVACE DUO	ACTAVIS	Allergan Plc	Bulgaria	CAPS 10 10MG 30	LEV 11.13	LEV 11.57	29 Feb 2016
Capsule	10MG	ramipril; amlodipine besylate	VIVACE DUO	ACTAVIS	Allergan Plc	Bulgaria	CAPS 5 10MG 30	LEV 9.10	LEV 8.83	31 Jan 2016
Tablet	5MG	amlodipine besylate; valsartan	VALTENSAM	ACTAVIS	Allergan Plc	Bulgaria	F.C.TABS 160 5MG 30	LEV 6.49		31 Mar 2017
Capsule	5MG	ramipril; amlodipine besylate	VIVACE DUO	ACTAVIS	Allergan Plc	Bulgaria	CAPS 5 5MG 30	LEV 6.86	LEV 6.70	31 Jan 2016
Tablet	10MG	amlodipine besylate; atorvastatin calcium	TORVALIPIN PLUS	ACTAVIS TEVA	Teva Pharmaceutical Industries Ltd	Romania	FC TABS 10MG 10MG 30	RON 12.77		31 Jul 2014
Tablet	5MG	amlodipine besylate; atorvastatin calcium	TORVALIPIN PLUS	ACTAVIS TEVA	Teva Pharmaceutical Industries Ltd	Romania	FC TABS 5MG 10MG 30	RON 10.96		31 Jul 2014
Tablet	10MG	amlodipine besylate	AMLODIPINA AUROBIN	AUROBINDO	Aurobindo Pharma Ltd	Romania	TABS 10MG 30	RON 3.29	RON5.10	31 Oct 2013
Tablet	5MG	amlodipine besylate	AMLODIPINA AUROBIN	AUROBINDO	Aurobindo Pharma Ltd	Romania	TABS 5MG 30	RON 1.94	RON 3.62	31 Oct 2013
Tablet	20MG	hydrochlorothiazide; amlodipine besylate; olmesartan medoxomil	TESPADAN HCT	BERLIN-CH/MENARINI	Menarini - Industrie Farma Riunite Srl	Bulgaria	F.C.T.5/12.5 20MG 28	LEV 40.30		30 Jun 2014
Tablet	20MG	amlodipine besylate; olmesartan medoxomil	INOVUM	BERLIN-CH/MENARINI	Menarini - Industrie Farma Riunite Srl	Romania	F.TABS 20MG 5MG 56	RON 168.80		31 Oct 2012

MANUFACTURING/SUPPLY: PLANNING TO MEET THE DEMAND FOR MEDICINES

Newport will help you identify new hypertensive products recently launched in Eastern Europe as tablets. Marketers profile and portfolio are also available so you can contact them and get all the medicines needed for your hospital at the best price.

Search Criteria : Dose Form [Tablet](#) or [Tablet, Delayed Release](#) or [Tablet, Extended Release](#) or [Tablet, Orally Disintegrating](#) or [Tablet, Orally Disintegrating, Delayed Release](#) or [Tablet, Sublingual](#) or [Tablet, Sublingual, Delayed Release](#) and Therapeutic Category (EphMRA) [C2 - Antihypertensives](#) and Launch Country [In Eastern Europe](#) and Pack Launch Date [is after 1/1/2015](#)

Search returned 965 records.

[Save Search](#)

Worldwide Pack Price Search Results

Pages: [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [21](#) [22](#) [23](#) [24](#) [25](#) [26](#) [27](#) [28](#) [29](#) [30](#) [31](#) [32](#) [33](#)

Excel Export

Dose Form	Strength	Active Ingredient	Trade Name	Marketer	Corporate Group	Launch Country	Pack Description	Latest Retail Pack Price	Latest Hospital Pack Price	Pack Launch Date
Tablet	50MG	sildenafil citrate	SILFECT	TK ILAC	TK ILAC	Turkey	FILMTAB 50MG 4	TL 74.81	TL 0.01	30 Apr 2017
Tablet, Extended Release	100MG	metoprolol succinate	METUZOK	SANDOZ	Novartis AG	Estonia	TABS PR 100MG 100	EUR 9.98		31 Mar 2017
Tablet	100MG	losartan potassium	LOSARTAN CANON	CANONPHARMA PRODUC	Zakritoe Aktsionernoe Obshestvo CanonPharma Production	Russia	FILM C.TABS 100MG 14	RUB 331.50		31 Mar 2017
Tablet	100MG	sildenafil citrate	VIVAYRA	BELUPO	Belupo	Russia	TABS CHEW 100MG	RUB 97.14		31 Mar 2017
Tablet	100MG	sildenafil citrate	VIVAYRA	BELUPO	Belupo	Russia	TABS CHEW 100MG 2	RUB 145.70		31 Mar 2017
Tablet	10MG	olmesartan medoxomil	OLSART	TCHAIKAPHARMA BG	Commercial League Healthcare Group	Bulgaria	FILM C.TABS 10MG 30	LEV 7.03	LEV 6.83	31 Mar 2017
Tablet	10MG	bisoprolol fumarate	BIBLOC FF8>>	FORFARM >>	Forfarm Sp Ltd	Poland	FILM C.TABS 10MG 30	ZLO 5.05	ZLO 0.95	31 Mar 2017
Tablet	10MG	amlodipine	AMLODIPINE	MEDISORB	Medisorb ZAO	Russia	TABS 10MG 50	RUB 86.12		31 Mar 2017

MANUFACTURING/SUPPLY: PLANNING TO MEET THE DEMAND FOR MEDICINES

Target searches in Newport will help you identify products available in other countries that haven't been launched in Romania, so you can identify new treatments for your patients. These flexible searches can be run by launched date, therapeutic category and country of interest, as shown next.

Search Criteria : Launched Products **In Germany** and **Not in Romania** and Pack Launch Date **is after 1/1/2015** and Therapeutic Category (EphMRA) **L1G - Monoclonal antibody antineoplastics** or **L1H - Protein kinase inhibitor antineoplastics**

Displaying 13 of 13 records

 Save Search

Search Results				
			Show: <input type="text" value="all products"/>	Country: <input type="text" value="Romania"/>
Pages: 1				<input type="button" value="Excel"/> <input type="button" value="Export"/>
Active Ingredients	Local Brand Name	Local Marketers	Product Details EphMRA TC	Market CI
blinatumomab	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
cabozantinib	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
ceritinib	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
cobimetinib hemifumarate	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
daratumumab	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
dinutuximab	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
elotuzumab	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
idelalisib	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
lenvatinib mesylate	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
olaratumab	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
osimertinib mesylate	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
palbociclib	None	No Data Available	Antineoplastics	<input type="button" value="View"/>
ramucirumab	None	No Data Available	Antineoplastics	<input type="button" value="View"/>

MANUFACTURING/SUPPLY: PLANNING TO MEET THE DEMAND FOR MEDICINES

Newport Constraint Date is calculated to make it easy to anticipate the date when generics will be launched in your market.

Patents in Newport will help you identify patent holders and expiry dates in your country.

Product Profile | Approvals | Launches | US Market Stats | R & D | **Patents** | US Patent Challenges | API | Pathways | Deals | Market CI | Regulations | Product Changes | Set Alert ▶

ambrisentan

Newport Constraint Date

Newport Constraint Date in Romania is **21 Apr 2018**. It is based on the expiry date of **Data + Marketing Exclusivity**.

[View SPCs](#) [View US Patents & Exclusivities associated with Approvals](#)

Worldwide Patent Families

Patents by Country

Show all patents in: Romania

Excel ▼ | Export | Filter Data

Active Ingredient	Patent Holder	Corporate Group Type	Patent Type	Patent Country	Estimated Expiry Date	Publication Number	Primary Patent Number	Patent Variables Indications ▼
ambrisentan	Gilead Sciences Inc	API/Big Pharma/Biotech	Component of Combination	Romania	14 Oct 2031	EP-02637664	WO-2012051559	Angina; Asthma; Atherosclerosis; Myocardial infarction; Pulmonary artery hypertension; Raynauds disease; Renal failure; Restenosis
ambrisentan	Gilead Sciences Inc	API/Big Pharma/Biotech	New use	Romania	11 Dec 2027	EP-02101777	WO-2008073928	Cardiovascular development disorder; Chronic obstructive pulmonary disease; Circadian rhythm sleep disorder; Histiocytoma; Interstitial lung disease; Lung embolism; Obesity hypoventilation syndrome; Pulmonary artery hypertension; Pulmonary hypertension; Thromboembolism
ambrisentan	Kern Pharma	Dose	Process; Process (intermediate)	Romania	28 Jun 2033	EP-02867214	WO-2014001511	Pulmonary artery hypertension
ambrisentan	Zydus-Cadila Healthcare Ltd	API/Biotech/US Generic	Process; Product (derivative)	Romania	12 Jul 2030	EP-02712865	WO-2011004402	Cardiac failure; Idiopathic pulmonary fibrosis; Pulmonary artery hypertension; Pulmonary hypertension; Renal failure
ambrisentan	Zydus-Cadila Healthcare Ltd	API/Biotech/US Generic	Process; Product (derivative)	Romania	12 Jul 2030	EP-02451786	WO-2011004402	Cardiac failure; Idiopathic pulmonary fibrosis; Pulmonary artery hypertension; Pulmonary hypertension; Renal failure

Important links and email addresses:

Cortellis (including clinical trials, regulatory, disease briefings) platforma access:

<https://www.cortellis.com/intelligence/login.do>

<https://www.e-nformation.ro/resurse/clarivate>

Date for online demonstration: **Tuesday, 28 November @ 11:30 am Bucharest**

Please click here to register: <https://clarivatesupport.webex.com/clarivatesupport/k2/j.php?MTID=te2e2bd6515e2d32e033acce8a8a2e969>

Clarivate support: ts.support.emea@clarivate.com



Bertrand Garrabe, Academic and Government Account Manager Europe | +44 207 433 4027 | bertrand.garrabe@clarivate.com clarivate.com
Monica Rosales, Customer Education Specialist | +44 7500 079 129 | monica.rosales@clarivate.com | clarivate.com